The posters presented at SITC 2025 feature trial designs for the Phase 2 and Phase 3 studies in advanced NSCLC patients receiving ateganosine followed by a checkpoint inhibitor, cemiplimab (Libtayo®).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback